|15.74||-0.4100||-2.54%||Vol 1.35M||1Y Perf -11.89%|
|Aug 11th, 2022 16:00 DELAYED|
|- -||- -%|
|Target Price||24.12||Analyst Rating||Moderate Buy 2.29|
|Potential %||53.24||Finscreener Ranking||★+ 43.89|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★+ 48.15|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★+ 47.64|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||22.13||Earnings Rating||Neutral|
|Market Cap||2.55B||Earnings Date||8th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.25|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.49M|
|Avg. Monthly Volume||1.78M|
|Avg. Quarterly Volume||2.64M|
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock closed at 15.74 per share at the end of the most recent trading day (a -2.54% change compared to the prior day closing price) with a volume of 1.35M shares and market capitalization of 2.55B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 580 people. ACADIA Pharmaceuticals Inc. CEO is Stephen R. Davis.
The one-year performance of ACADIA Pharmaceuticals Inc. stock is -11.89%, while year-to-date (YTD) performance is -32.56%. ACAD stock has a five-year performance of -49.57%. Its 52-week range is between 12.24 and 28.055, which gives ACAD stock a 52-week price range ratio of 22.13%
ACADIA Pharmaceuticals Inc. currently has a PE ratio of -11.50, a price-to-book (PB) ratio of 5.55, a price-to-sale (PS) ratio of 6.43, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.41%, a ROC of -37.11% and a ROE of -43.62%. The company’s profit margin is -46.65%, its EBITDA margin is -43.30%, and its revenue ttm is $377.84 Million , which makes it $2.34 revenue per share.
Of the last four earnings reports from ACADIA Pharmaceuticals Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.25 for the next earnings report. ACADIA Pharmaceuticals Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for ACADIA Pharmaceuticals Inc. is Moderate Buy (2.29), with a target price of $24.12, which is +53.24% compared to the current price. The earnings rating for ACADIA Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ACADIA Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ACADIA Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 20.16, ATR14 : 0.99, CCI20 : 115.74, Chaikin Money Flow : 0.03, MACD : 0.14, Money Flow Index : 65.92, ROC : 13.49, RSI : 45.60, STOCH (14,3) : 74.13, STOCH RSI : 0.76, UO : 62.16, Williams %R : -25.87), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ACADIA Pharmaceuticals Inc. in the last 12-months were: Austin D. Kim (Option Excercise at a value of $0), Austin D. Kim (Sold 3 606 shares of value $79 939 ), Brendan P. Teehan (Option Excercise at a value of $0), Brendan P. Teehan (Sold 1 562 shares of value $33 671 ), Elizabeth Garofalo (Option Excercise at a value of $0), James K. Kihara (Option Excercise at a value of $0), James K. Kihara (Sold 1 384 shares of value $36 270 ), Mark Schneyer (Option Excercise at a value of $0), Mark Schneyer (Sold 553 shares of value $13 161 ), Srdjan Stankovic (Option Excercise at a value of $0), Srdjan Stankovic (Sold 10 444 shares of value $209 042 ), Stephen R. Davis (Option Excercise at a value of $0), Stephen R. Davis (Sold 16 092 shares of value $330 463 )
Tue, 09 Aug 2022 04:45 GMT ACADIA Pharmaceuticals (ACAD) Receives a Buy from JMP Securities- TipRanks. All rights reserved.
Mon, 11 Jul 2022 12:39 GMT ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from SVB Securities- TipRanks. All rights reserved.
Sat, 09 Jul 2022 01:45 GMT Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), BioCryst (BCRX) and Cigna (CI)- TipRanks. All rights reserved.
Tue, 21 Jun 2022 12:26 GMT ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from JMP Securities- TipRanks. All rights reserved.
Thu, 16 Jun 2022 14:22 GMT Why Did Acadia Pharmaceuticals Shares Gain 15%- TipRanks. All rights reserved.
Wed, 15 Jun 2022 15:15 GMT Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Boston Scientific (BSX)- TipRanks. All rights reserved.
Wed, 18 May 2022 13:24 GMT ACADIA Pharmaceuticals: No Upturn in Sight- TipRanks. All rights reserved.
Sun, 08 May 2022 15:22 GMT ACADIA Pharmaceuticals (ACAD) Receives a Buy from SVB Securities- TipRanks. All rights reserved.
Thu, 05 May 2022 10:29 GMT ACADIA Pharmaceuticals (ACAD) Gets a Buy Rating from H.C. Wainwright- TipRanks. All rights reserved.
Sun, 01 May 2022 16:35 GMT Analysts Are Bullish on These Healthcare Stocks: ACADIA Pharmaceuticals (ACAD), Compugen (CGEN)- TipRanks. All rights reserved.
Tue, 19 Apr 2022 10:05 GMT ACADIA Pharmaceuticals (ACAD) Receives a Hold from Needham- TipRanks. All rights reserved.
Tue, 19 Apr 2022 04:25 GMT Analysts Top Healthcare Picks: ACADIA Pharmaceuticals (ACAD), CTI BioPharma (CTIC)- TipRanks. All rights reserved.
Sat, 09 Apr 2022 01:50 GMT RBC Capital Believes ACADIA Pharmaceuticals (ACAD) Still Has Room to Grow- TipRanks. All rights reserved.
Mon, 04 Apr 2022 10:55 GMT ACADIA Pharmaceuticals (ACAD) Gets a Hold Rating from Needham- TipRanks. All rights reserved.
Wed, 09 Mar 2022 20:40 GMT ACADIA Pharmaceuticals (ACAD) Receives a Hold from Berenberg Bank- TipRanks. All rights reserved.
Mon, 07 Mar 2022 16:42 GMT ACADIA Pharmaceuticals (ACAD) Receives a Hold from Goldman Sachs- TipRanks. All rights reserved.
Wed, 02 Mar 2022 01:45 GMT Analysts Offer Insights on Healthcare Companies: ACADIA Pharmaceuticals (ACAD) and Beam Therapeutics (BEAM)- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.